Verana Health Named Top Innovator in 2025 Frost Radar for Real-World Evidence Solutions
Event summary
- Verana Health recognized as innovation leader in Frost Radar™: Life Sciences Real-World Evidence Solutions 2025 report.
- COTA merger expands therapeutic footprint to include oncology, complementing existing ophthalmology, urology, and neurology data.
- Combined entity serves 17 of top 20 global biopharma companies with access to 95M+ patients and 20K+ clinicians.
- Exclusive partnerships with American Academy of Ophthalmology IRIS® Registry and AUA Quality (AQUA)® Registry.
- Expanded network access to 30+ Academic Medical Centers, increasing accessible oncology patients to 10M+.
The big picture
Verana Health's recognition as an innovation leader underscores the growing importance of real-world evidence in life sciences. The COTA merger significantly expands its therapeutic footprint, positioning it as a key player in oncology data. This strategic move aligns with broader industry trends toward data-driven clinical research and regulatory decision-making, enhancing Verana Health's competitive edge in the biopharma sector.
What we're watching
- Integration Challenges
- How Verana Health will integrate COTA's oncology data with its existing specialty therapeutic areas.
- Regulatory Influence
- Whether the combined regulatory expertise will position Verana Health as a top-tier FDA partner.
- Market Expansion
- The pace at which Verana Health can leverage its expanded network to accelerate clinical trial solutions.
Related topics